Literature DB >> 7537544

Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone.

D R Harder1, W B Campbell, R J Roman.   

Abstract

The metabolism of arachidonic acid (AA) into vasoactive products by cyclooxygenase and lipoxygenase enzymes has been well described, as has their biological relevance. Recently, a number of studies have demonstrated the ability of cytochrome P-450 (P450) enzymes to metabolize AA into biologically important regulators of vascular tone. There are two categories of vasoactive P450 metabolites, namely those catalyzed by epoxygenase enzymes which generate epoxyeicosatrienoic acids (EETs) and those enzymes which generate hydroxyeicosatetraenoic acids (HETEs). Except for 20-HETE, P450 metabolites of AA occur as stereo- and regioisomers which determine, to some extent, their biological activity. 5,6-, 8,9-, 11,12- and 14,15-EETs are generally potent dilators in a number of vascular beds with a sensitivity which appears to increase as the vasculature decreases in size toward capillaries. HETEs, such as 12R- and 20-HETE, can be potent activators of vascular tissue with 20-HETE contracting cerebral and renal microvessels at concentrations of < 10(-10) M. Both EETs and HETEs can be made by vascular and extravascular tissue. Available data suggests that EETs are formed by endothelial and parenchymal tissue while HETEs can be endogenously formed in arterial muscle where they appear to act as second messengers. This review will discuss the molecular biology, stereochemistry, biological activity and importance of P450 metabolites of AA as para- and autocrine controllers of organ blood flow. We will also discuss the large diversity of P450 enzyme isoforms and how such diversity can provide for precise physiological control of vascular tone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7537544     DOI: 10.1159/000159080

Source DB:  PubMed          Journal:  J Vasc Res        ISSN: 1018-1172            Impact factor:   1.934


  63 in total

1.  HET0016, a potent and selective inhibitor of 20-HETE synthesizing enzyme.

Authors:  N Miyata; K Taniguchi; T Seki; T Ishimoto; M Sato-Watanabe; Y Yasuda; M Doi; S Kametani; Y Tomishima; T Ueki; M Sato; K Kameo
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

2.  Increase of 20-HETE synthase after brain ischemia in rats revealed by PET study with 11C-labeled 20-HETE synthase-specific inhibitor.

Authors:  Toshiyuki Kawasaki; Toshiyuki Marumo; Keiko Shirakami; Tomoko Mori; Hisashi Doi; Masaaki Suzuki; Yasuyoshi Watanabe; Shigeyuki Chaki; Atsuro Nakazato; Yukio Ago; Hitoshi Hashimoto; Toshio Matsuda; Akemichi Baba; Hirotaka Onoe
Journal:  J Cereb Blood Flow Metab       Date:  2012-06-06       Impact factor: 6.200

3.  Role of ω-hydroxylase in adenosine-mediated aortic response through MAP kinase using A2A-receptor knockout mice.

Authors:  Dovenia S Ponnoth; Mohammed A Nayeem; Swati S Kunduri; Stephen L Tilley; Darryl C Zeldin; Catherine Ledent; S Jamal Mustafa
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-07       Impact factor: 3.619

4.  20-Hydroxyeicosatetraenoic acid potentiates stretch-induced contraction of canine basilar artery via PKC alpha-mediated inhibition of KCa channel.

Authors:  Kazuo Obara; Masayo Koide; Koichi Nakayama
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

5.  Inhibition of soluble epoxide hydrolase limits niacin-induced vasodilation in mice.

Authors:  Ahmet B Inceoglu; Heather L Clifton; Jun Yang; Christine Hegedus; Bruce D Hammock; Saul Schaefer
Journal:  J Cardiovasc Pharmacol       Date:  2012-07       Impact factor: 3.105

6.  Mechanisms of L-NG nitroarginine/indomethacin-resistant relaxation in bovine and porcine coronary arteries.

Authors:  W F Graier; S Holzmann; B G Hoebel; W R Kukovetz; G M Kostner
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

7.  Cytochrome P450 2J2 is highly expressed in hematologic malignant diseases and promotes tumor cell growth.

Authors:  Chen Chen; Xin Wei; Xiaoquan Rao; Jun Wu; Shenglan Yang; Fuqiong Chen; Ding Ma; Jianfeng Zhou; Ryan T Dackor; Darryl C Zeldin; Dao Wen Wang
Journal:  J Pharmacol Exp Ther       Date:  2010-10-28       Impact factor: 4.030

Review 8.  Antiinflammatory and neuroprotective actions of COX2 inhibitors in the injured brain.

Authors:  Kenneth I Strauss
Journal:  Brain Behav Immun       Date:  2007-11-08       Impact factor: 7.217

Review 9.  Targeted lipidomic strategies for oxygenated metabolites of polyunsaturated fatty acids.

Authors:  Giuseppe Astarita; Alexandra C Kendall; Edward A Dennis; Anna Nicolaou
Journal:  Biochim Biophys Acta       Date:  2014-12-05

10.  Effects of cytochrome P450 inhibitors on EDHF-mediated relaxation in the rat hepatic artery.

Authors:  P M Zygmunt; G Edwards; A H Weston; S C Davis; E D Högestätt
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.